格隆汇1月16日｜有投资者在互动平台向翔宇医疗提问：目前公司的脑机接口项目已进入多少家医疗机 构？翔宇医疗回复称，公司相关产品已进入600多家三甲医院，2026年目标覆盖超千家三甲医院，商业 化进程和临床落地加速。 ...

格隆汇1月16日｜今日医疗设备板块走势震荡，截至发稿，医疗设备ETF(159873)成交额4859.76万元， 换手率超26%，在同标的产品中处断层第一，且盘中获资金净申购5700万份，此前6日连续获资金净流 入，累计"吸金"超6000万元，近10日净流率60%。芯片板块强势上涨，带动芯片ETF天弘(159310）标的 指数上涨3.08%。 消息面上: ①台积电第四季度财报及展望远超过预期，清晰释放出人工智能热潮将持续的信号。台积电第四季度净 利润同比大幅增长35%，创下历史新高，且2026年资本支出计划最高将达560亿美元，较2025年大幅增 长37%，创下该公司的史上新高。 ③翔宇医疗预计2026年有5-6款AI理疗机器人系列产品陆续下证。 同标的规模第一的医疗设备ETF（159873）跟踪医疗保健指数，脑机接口含量较高，占比超17%！科技 属性强，成分股中科创版+创业板含量占比近80%。在国产创新替代、出口加速及新技术加持下，有望 迎来全面估值修复。其覆盖三博脑科、翔宇医疗、伟思医疗等脑机接口核心概念。 芯片ETF天弘(159310）跟踪中证芯片产业指数，覆盖芯片设计、制造、封装测试等核心环节，直接受 ...

Group 1 - The medical device sector is experiencing volatility, with the medical device ETF (159873) achieving a trading volume of 48.6 million yuan and a turnover rate exceeding 26%, leading in its category [1] - The medical device ETF has seen a net inflow of over 60 million yuan in the past 10 days, with a net subscription of 57 million units in the latest session [1] - TSMC's fourth-quarter earnings report exceeded expectations, with a net profit growth of 35% year-on-year, signaling a sustained AI boom [1] Group 2 - The medical device ETF (159873) tracks the healthcare index and has a high concentration of brain-computer interface stocks, accounting for over 17% of its holdings [2] - The ETF includes significant exposure to innovative domestic companies and is expected to undergo a comprehensive valuation recovery due to accelerated exports and new technologies [2] - The chip ETF Tianhong (159310) tracks the semiconductor industry index and benefits directly from domestic substitution and technological breakthroughs in the semiconductor sector [2]

Group 1 - The core viewpoint of the news is that Xiangyu Medical's stock has experienced fluctuations, with a recent decline of 2.02% and a year-to-date increase of 25.95% [1] - As of January 16, the stock price is reported at 76.20 yuan per share, with a total market capitalization of 12.192 billion yuan [1] - The company has seen a net outflow of main funds amounting to 20.5363 million yuan, with significant selling pressure from large orders [1] Group 2 - Xiangyu Medical, established on March 20, 2002, specializes in the research, production, and sales of rehabilitation medical devices, with a revenue composition of 67.79% from rehabilitation therapy equipment [2] - The company belongs to the pharmaceutical and biological industry, specifically in the medical device sector, and is involved in various concept sectors including brain-machine interface and robotics [2] - As of September 30, the company reported a revenue of 537 million yuan for the first nine months of 2025, reflecting a year-on-year growth of 6.00%, while the net profit attributable to shareholders decreased by 40.09% to 43.9815 million yuan [2] Group 3 - Since its A-share listing, Xiangyu Medical has distributed a total of 277 million yuan in dividends, with 157 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders increased by 51.24% to 9,531, while the average circulating shares per person decreased by 33.88% to 16,787 shares [2][3] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 918,600 shares, an increase of 12,530 shares compared to the previous period [3]

Group 1 - In the past five trading days, a total of 165 companies were investigated by institutions, with significant interest in Xiangyu Medical, Haitan Ruisheng, and Aipeng Medical [1][2] - Among the companies investigated, 35 received attention from more than 20 institutions, with Xiangyu Medical being the most popular, attracting 208 institutions [1][2] - The types of institutions involved in the investigations included 143 from securities companies, 123 from fund companies, and 59 from private equity firms [1] Group 2 - In terms of investigation frequency, two companies, Binglun Environment and Taihe New Materials, were investigated four times, indicating high interest [2] - Out of the stocks investigated by more than 20 institutions, 11 saw net capital inflows, with Liou Co. receiving the highest net inflow of 1.176 billion yuan [2] - Among the stocks investigated, 28 experienced price increases, with Liou Co., Aipeng Medical, and Hehe Information showing significant gains of 53.39%, 33.24%, and 32.40% respectively [2] Group 3 - Three companies among those investigated released performance forecasts, with two expecting profit increases; Changlan Technology projected a net profit of 145 million yuan, representing a year-on-year increase of 94.16% [2]

Group 1 - The core viewpoint of the article is that Xiangyu Medical has successfully entered the list of projects for the 2025 Artificial Intelligence Medical Device Innovation Task with its "Closed-loop Transcranial Stimulation System for Treatment-Resistant Depression" project [2] Group 2 - The project is led by the company and aims to address treatment-resistant depression, indicating a focus on innovative solutions in the mental health sector [2] - The inclusion in the innovation task list highlights the company's commitment to advancing medical technology and its potential impact on the healthcare industry [2]

证券日报网讯 1月15日，翔宇医疗在互动平台回答投资者提问时表示，公司相关产品已进入600多家三 甲医院，2026年目标覆盖超千家三甲医院，商业化进程和临床落地加速。 （文章来源：证券日报） ...

Core Insights - The brain-computer interface (BCI) sector has seen over a 30% increase in just a few trading days, with companies like Xiangyu Medical and Mylande doubling in value, reflecting a more than 100% rise since early 2025, indicating a rapid industrialization of a technology once confined to science fiction [1][2] - Recent clinical breakthroughs in invasive BCIs have enabled paralyzed patients to perform tasks through thought, while non-invasive technologies are entering daily life, marking a significant shift in health management from monitoring to guidance [1][6] - China is set to implement its first BCI medical device industry standards on January 1, 2026, paving the way for technology transformation and clinical application [1][5] Industry Overview - The BCI sector is emerging as a strategic battleground between the US and China, integrating neuroscience, artificial intelligence, and microelectronics, with implications for healthcare, military, and cognitive enhancement [2] - The global BCI market was valued at $1.5 billion in 2021 and is projected to grow to $3.3 billion by 2027, with a compound annual growth rate (CAGR) of approximately 17.35% [6][9] - In China, the BCI market is expected to reach 3.2 billion yuan in 2024, with an 18.81% year-on-year growth, and further growth to 3.8 billion yuan in 2025 and 4.6 billion yuan in 2026 [6] Technological Developments - Companies like Neuralink are innovating with minimally invasive surgical techniques for BCI devices, while MergeLabs focuses on non-invasive ultrasound technology [3][9] - The BCI technology landscape is diversifying, with various companies exploring both invasive and non-invasive pathways, accelerating global market expansion [9][10] - The development of flexible microelectrodes and wireless transmission modules is crucial for the future of BCI technology, with significant cost reductions expected in the coming years [12][14] Application Scenarios - BCIs are being utilized in various applications, including cognitive rehabilitation, emotional assessment, and even potential replacements for certain neurological medications, indicating a shift towards digital therapies [21][22] - The medical health sector remains the largest application area, accounting for approximately 47.62% of BCI applications, with products entering clinical pathways and regulatory approval processes [20] - Non-medical applications are also expanding, with consumer electronics and entertainment sectors beginning to adopt BCI technologies, indicating a broadening of market opportunities [21] Investment Opportunities - Companies with strong engineering capabilities and real orders are positioned to benefit from the BCI boom, as the sector approaches a critical commercialization phase [23][24] - Notable players include Micron Brain Science, which is focusing on invasive BCI technologies, and Xiangyu Medical, which is pursuing a non-invasive, full-chain self-research approach [24][25] - The market is expected to undergo significant consolidation, with companies that lack foundational technology likely to be eliminated, while those with robust product offerings and clinical pathways will thrive [26][27]

Core Insights - The A-share market has seen increased activity and emerging themes following the "opening red" in 2026, with a shift in broker research focus towards AI applications and brain-computer interfaces (BCI) [1][2] Group 1: Broker Research Trends - Broker research is increasingly focusing on high-growth industries, performance certainty, and valuation attractiveness, reflecting three major trends: a balanced investment style, a shift from speculative trading to performance realization, and a focus on domestic self-sufficiency and global competitiveness [2][7] - From January 1 to January 14, 2026, over 260 A-share companies were researched by institutions, with more than 230 receiving broker attention, highlighting a strong interest in companies like 壹网壹创, 成都先导, and 翔宇医疗 [3][4] Group 2: Key Companies and Their Focus - 壹网壹创, a leading company in the GEO concept, received attention from 27 brokers, focusing on its R&D investments and partnerships with platforms like Alibaba [4][5] - Other notable companies include 凯盛科技 and 海天瑞声, which received 22 and 21 broker inquiries respectively, with a focus on technological innovation in their respective fields [4] - Companies like 爱朋医疗, 中集集团, and 振江股份 also garnered significant broker interest, indicating a diverse range of sectors being explored [4] Group 3: Market Performance and Investment Opportunities - The AI application index and GEO index saw increases of 18.30% and 44.14% respectively from January 5 to January 15, 2026, indicating strong market interest in these sectors [8] - The global GEO market is projected to reach $24 billion by 2026 and $100 billion by 2030, with domestic expectations of reaching 11.1 billion yuan in 2026 [10] - Investment opportunities are emerging in the AI marketing sector, with a focus on companies that can leverage marketing technology and content creation [10][11] Group 4: Brain-Computer Interface (BCI) Insights - The BCI sector is expected to see significant growth, with applications in various fields such as healthcare and consumer products, driven by technological advancements and diverse application scenarios [12][13] - The global BCI market is projected to reach $7.63 billion by 2029, highlighting the potential for substantial investment opportunities in this emerging field [13]

Group 1 - The company, Xiangyu Medical, confirmed its participation in the Ministry of Industry and Information Technology's AI medical device initiative, specifically for a project targeting treatment-resistant depression with a closed-loop transcranial stimulation system [2] - The project led by the company has successfully made it to the list of innovative tasks for AI medical devices set for 2025 [2]